VVY — Vivoryon Therapeutics NV Cashflow Statement
0.000.00%
Last trade - 00:00- €59.30m
- €30.61m
- -€3.62m
Annual cashflow statement for Vivoryon Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.82 | -16.5 | -12.2 | -28.2 | -28.3 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.072 | 0.653 | 1.37 | 6.19 | 6.78 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.94 | 1.7 | -0.565 | 0.211 | 0.091 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -11.6 | -14 | -11.3 | -21.8 | -21.5 |
| Capital Expenditures | -0.047 | -0.064 | -0.028 | -0.013 | -0.514 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | -0.576 | — | — | -10 |
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.047 | -0.64 | -0.028 | -0.013 | -10.5 |
| Financing Cash Flow Items | -1.83 | 0 | -1.88 | -2.53 | -2.1 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 49.4 | -0.09 | -0.827 | 33.4 | 24.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 37.7 | -15.2 | -11.6 | 11.9 | -7.99 |